FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360600189> ?p ?o ?g. }

• W4360600189 endingPage "e234254" @default.
• W4360600189 startingPage "e234254" @default.
• W4360600189 abstract "Importance The prognosis for patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is dismal, due in part to chemoresistance. Bacteria-mediated mechanisms of chemoresistance suggest a potential role for antibiotics in modulating response to chemotherapy. Objective To evaluate whether use of peritreatment antibiotics is associated with survival among patients with metastatic PDAC treated with first-line gemcitabine or fluorouracil chemotherapy. Design, Setting, and Participants Using the population-based Surveillance, Epidemiology, and End Results–Medicare linked database, this retrospective cohort study analyzed data for patients diagnosed with PDAC between January 1, 2007, and December 31, 2017. Data analysis was conducted between September 1, 2021, and January 15, 2023. The population-based sample included 3850 patients with primary metastatic PDAC treated with first-line gemcitabine or fluorouracil chemotherapy. Patients who received antibiotics were matched based on propensity scores to patients who did not receive antibiotics. Exposures Receipt of 5 or more days of oral antibiotics or 1 injectable antibiotic in the month before or after beginning first-line chemotherapy. Main Outcomes and Measures Overall survival and cancer-specific survival. The end of follow-up was December 31, 2019, for overall survival and December 31, 2018, for cancer-specific survival. Results Of the 3850 patients treated with first-line gemcitabine (3150 [81.8%]) or fluorouracil (700 [18.2%]), 2178 (56.6%) received antibiotics. The mean (SD) age at diagnosis was 74.2 (5.8) years and patients were predominantly women (2102 [54.6%]), White (3396 [88.2%]), and from metropolitan areas (3393 [88.1%]) in the northeastern or western US (2952 [76.7%]). In total, 1672 propensity-matched pairs were analyzed. Antibiotic receipt was associated with an 11% improvement in overall survival (hazard ratio [HR], 0.89; 95% CI, 0.83-0.96; P = .003) and a 16% improvement in cancer-specific survival (HR, 0.84; 95% CI, 0.77-0.92; P &amp;lt; .001) among patients treated with gemcitabine. In contrast, there was no association between antibiotic receipt and overall survival (HR, 1.08; 95% CI, 0.90-1.29; P = .41) or cancer-specific survival (HR, 1.12; 95% CI, 0.90-1.36; P = .29) among patients treated with fluorouracil. In a subgroup of gemcitabine-treated patients who received antibiotics, nonpenicillin β-lactams were associated with an 11% survival benefit (HR, 0.89; 95% CI, 0.81-0.97; P = .01). Conclusions and Relevance In this cohort study, receipt of perichemotherapy antibiotics was associated with improved survival among patients treated with gemcitabine, but not fluorouracil, suggesting that antibiotics may modulate bacteria-mediated gemcitabine resistance and have the potential to improve PDAC outcomes." @default.
• W4360600189 created "2023-03-24" @default.
• W4360600189 creator A5000703280 @default.
• W4360600189 creator A5018088794 @default.
• W4360600189 creator A5018207359 @default.
• W4360600189 creator A5033612339 @default.
• W4360600189 creator A5048973199 @default.
• W4360600189 creator A5049808872 @default.
• W4360600189 creator A5049813870 @default.
• W4360600189 creator A5055627666 @default.
• W4360600189 creator A5082611842 @default.
• W4360600189 date "2023-03-23" @default.
• W4360600189 modified "2023-10-16" @default.
• W4360600189 title "Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy" @default.
• W4360600189 cites W1591554783 @default.
• W4360600189 cites W1917229050 @default.
• W4360600189 cites W1945551477 @default.
• W4360600189 cites W1968812902 @default.
• W4360600189 cites W1976409944 @default.
• W4360600189 cites W2000445173 @default.
• W4360600189 cites W2000991311 @default.
• W4360600189 cites W2030323580 @default.
• W4360600189 cites W2030568262 @default.
• W4360600189 cites W2095960366 @default.
• W4360600189 cites W2151253787 @default.
• W4360600189 cites W2153456263 @default.
• W4360600189 cites W2165480504 @default.
• W4360600189 cites W2484995089 @default.
• W4360600189 cites W2606663123 @default.
• W4360600189 cites W2625337046 @default.
• W4360600189 cites W2742147437 @default.
• W4360600189 cites W2756403351 @default.
• W4360600189 cites W2765314233 @default.
• W4360600189 cites W2769094265 @default.
• W4360600189 cites W2771477016 @default.
• W4360600189 cites W2783393271 @default.
• W4360600189 cites W2790589159 @default.
• W4360600189 cites W2795186863 @default.
• W4360600189 cites W2897664707 @default.
• W4360600189 cites W2949882994 @default.
• W4360600189 cites W2955224282 @default.
• W4360600189 cites W3091743810 @default.
• W4360600189 cites W3178490306 @default.
• W4360600189 cites W3205211596 @default.
• W4360600189 cites W4206758880 @default.
• W4360600189 cites W4206841660 @default.
• W4360600189 cites W4226237761 @default.
• W4360600189 cites W4245185457 @default.
• W4360600189 cites W4248150497 @default.
• W4360600189 cites W4248328059 @default.
• W4360600189 cites W4307564407 @default.
• W4360600189 doi "https://doi.org/10.1001/jamanetworkopen.2023.4254" @default.
• W4360600189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36951863" @default.
• W4360600189 hasPublicationYear "2023" @default.
• W4360600189 type Work @default.
• W4360600189 citedByCount "5" @default.
• W4360600189 countsByYear W43606001892023 @default.
• W4360600189 crossrefType "journal-article" @default.
• W4360600189 hasAuthorship W4360600189A5000703280 @default.
• W4360600189 hasAuthorship W4360600189A5018088794 @default.
• W4360600189 hasAuthorship W4360600189A5018207359 @default.
• W4360600189 hasAuthorship W4360600189A5033612339 @default.
• W4360600189 hasAuthorship W4360600189A5048973199 @default.
• W4360600189 hasAuthorship W4360600189A5049808872 @default.
• W4360600189 hasAuthorship W4360600189A5049813870 @default.
• W4360600189 hasAuthorship W4360600189A5055627666 @default.
• W4360600189 hasAuthorship W4360600189A5082611842 @default.
• W4360600189 hasBestOaLocation W43606001891 @default.
• W4360600189 hasConcept C121608353 @default.
• W4360600189 hasConcept C126322002 @default.
• W4360600189 hasConcept C141071460 @default.
• W4360600189 hasConcept C143998085 @default.
• W4360600189 hasConcept C167135981 @default.
• W4360600189 hasConcept C2776694085 @default.
• W4360600189 hasConcept C2780210213 @default.
• W4360600189 hasConcept C2780258809 @default.
• W4360600189 hasConcept C2908647359 @default.
• W4360600189 hasConcept C501593827 @default.
• W4360600189 hasConcept C71924100 @default.
• W4360600189 hasConcept C72563966 @default.
• W4360600189 hasConcept C86803240 @default.
• W4360600189 hasConcept C89423630 @default.
• W4360600189 hasConcept C99454951 @default.
• W4360600189 hasConceptScore W4360600189C121608353 @default.
• W4360600189 hasConceptScore W4360600189C126322002 @default.
• W4360600189 hasConceptScore W4360600189C141071460 @default.
• W4360600189 hasConceptScore W4360600189C143998085 @default.
• W4360600189 hasConceptScore W4360600189C167135981 @default.
• W4360600189 hasConceptScore W4360600189C2776694085 @default.
• W4360600189 hasConceptScore W4360600189C2780210213 @default.
• W4360600189 hasConceptScore W4360600189C2780258809 @default.
• W4360600189 hasConceptScore W4360600189C2908647359 @default.
• W4360600189 hasConceptScore W4360600189C501593827 @default.
• W4360600189 hasConceptScore W4360600189C71924100 @default.
• W4360600189 hasConceptScore W4360600189C72563966 @default.
• W4360600189 hasConceptScore W4360600189C86803240 @default.
• W4360600189 hasConceptScore W4360600189C89423630 @default.
• W4360600189 hasConceptScore W4360600189C99454951 @default.

• next